Arsenal has extended their technical partnership with Adidas their kit supplier until 2030.
The financial terms of the new deal have not been reported.
According to Juliet Slot, Arsenal’s chief commercial officer, the long-term nature of our extension means there’s a real commitment to collaboration, with a strong focus on growing women’s football and developing our sustainability strategy.
Adidas replaced rival Puma as Arsenal’s kit supplier ahead of the 2019/20 season with a five-year deal reportedly worth $66.33 million, totaling US$332.12 million.
Adidas will also lend its expertise to support Arsenal’s sustainability strategy, with the brand currently working towards its goal to replace all virgin polyester with recycled polyester in its products by 2024 wherever possible.
Arsenal and Adidas have collaborated on other initiatives.
In January, the two groups launched the ‘No More Red’ campaign, which saw Arsenal wear all-white kits to raise awareness of knife crime in London.


J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth
Japan Economy Grows 1.1% in Q2 as Consumer Spending Stalls
S&P 500 Hits Record High as Soft Inflation Data Eases Fed Rate Hike Fears
Republican Lawmakers Urge National Guard Role for World Cup Drone Security
FBI Faces Historic Security Challenge Ahead of 2026 FIFA World Cup
Oil Prices Steady as Strait of Hormuz Traffic Slows Amid US-Iran Conflict
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake
Trump Draws Cheers at Ryder Cup as U.S. Trails Europe After Opening Day
Gold Prices Rise as Weak US Data and Hormuz Risks Boost Safe-Haven Demand
FIFA Defends Balogun Ban Suspension After Trump Praise Sparks World Cup Controversy
Trump’s U.S. Open Visit Delays Final, Fans Face Long Security Lines
Alphabet’s SpaceX Investment Soars 100-Fold to $94 Billion
Morgan Stanley Sees Fed Holding Rates as U.S. Inflation Cools
Barclays Warns U.S. Stock Rally May Be Detached From Fundamentals
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 



